List of diseases covered by the Aotearoa Immunisation Register

IPS body site value set. This value set includes a set of codes from SNOMED CT that may be used to represent body sites (e.g., for laboratory specimen collection).

Commonly encountered UCUM units (for purposes of helping populate look ups.

Preferred value set for Condition/Diagnosis severity grading.

HL7 LOINC value set for smoking status. Based on the HL7 Vocab and Structured Doc WG (formerly TC) consensus - per US CDC submission 7/12/2012 for smoking status terms.

The source from where the date of death was sourced

Whether the application produces or consumes documents.

This valueset can be used for the collection of languages spoken by patients and providers. It contains the full set of ISO 639-2 language codes. It also contains ISO 639-3 codes for Cantonese(yue), Mandarin(cmn) and New Zealand Sign language (nzs) as these languages are commonly recorded by health providers in New Zealand. To request other ISO 639-3 codes to be added to the valueset contact stamdards@tewhatuora.govt.nz.

iso 639-2 and 639-3 language codes

This value set includes codes from SNOMED Clinical Terms®: descendants of 373873005 |Pharmaceutical / biologic product (product)| excluding the descendants of 787859002 |Vaccine product (medicinal product)|.

This value set includes codes from SNOMED Clinical Terms®: all descendants of 410942007 | Drug or medicament (substance)|.
Future implementations should consider ISO 11238 Health informatics – Identification of medicinal products – Data elements and structures for the unique identification and exchange of regulated information on substances.

A clinical regional lymph node stage (cN) of a breast tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a breast tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

The clinical stage groups that describe how far a breast cancer has grown and spread before initiation of treatment, using AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a breast tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a breast tumour, using the AJCC cancer staging manual (8th edition).

AJCC (8th edition) residual tumour (R) category.

A clinical distant metastasis stage (cM) of a cervix uteri tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a cervix uteri tumour, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a cervix uteri cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a female genital tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a female genital tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a corpus uteri adenosarcoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a corpus uteri adenosarcoma, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a corpus uteri carcinoma and carcinosarcoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a corpus uteri carcinoma and carcinosarcoma has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a corpus uteri before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a corpus uteri leiomyosarcoma and endometrial stromal sarcoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a corpus uteri leiomyosarcoma and endometrial stromal sarcoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a corpus uteri leiomyosarcoma and endometrial stromal sarcoma, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a corpus uteri tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a corpus uteri tumour, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a corpus uteri cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a gestational trophoblastic tumour, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a gestational trophoblastic cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a ovary, fallopian tube and primary peritoneal carcinoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a ovary, fallopian tube and primary peritoneal carcinoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a ovary, fallopian tube and primary peritoneal carcinoma, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a ovary, falliopian and primary peritoneal carcinoma, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a ovary, fallopian tube and peritoneal carcinoma has grown and spread, using AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a female genital tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a female genital tumour, using the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a female genital cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a vagina tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a vagina tumour, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a vagina cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a vulva tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a vulva tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a vulva tumour, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a vulva tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a vulva tumour, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a vulva cancer has grown and spread, using AJCC cancer staging manual (8th edition).

The clinical stage group that describe how far a gastrointestinal cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a gastrointestinal colon and rectum tumour before initiation of treatment, using chapter 20 of the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a gastrointestinal colon and rectum tumour before initiation of treatment, using chapter 20 of the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a gastrointestinal colon and rectum tumour before initiation of treatment, using chapter 20 of the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a gastrointestinal colon and rectum tumour before initiation of treatment, using chapter 20 of the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a gastrointestinal colon and rectum tumour before initiation of treatment, using chapter 20 of the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a gastrointestinal colon and rectum cancer has grown and spread, using chapter 20 of the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A post therapy or post neoadjuvant therapy pathological tumour stage group that describe how far a gastrointestinal cancer has grown and spread, using AJCC cancer staging manual (8th edition).

The pathological stage group that describe how far a gastrointestinal cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a gastrointestinal stromal tumour (GIST) before initiation of treatment, using chapter 43 of the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a gastrointestinal stromal tumour (GIST) before initiation of treatment, using chapter 43 of the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a gastrointestinal stromal tumour (GIST) before initiation of treatment, using chapter 43 of the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a gastrointestinal stromal tumour (GIST) before initiation of treatment, using chapter 43 of the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a gastrointestinal stromal tumour (GIST) before initiation of treatment, using chapter 43 of the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a Hodgkin or non Hodgkin lymphoma has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a haematologic cancer before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a haematologic cancer before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a haematologic cancer before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a cutaneous B cell or T cell lymphoma (non mycosis fungoides and non sezary syndrome), using the AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a mycosis fungoides or sezary syndrome cutaneous lymphoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a mycosis fungoides or sezary syndrome cutaneous lymphoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a mycosis fungoides or sezary syndrome cutaneous lymphoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a mycosis fungoides or sezary syndrome cutaneous lymphoma, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a mycosis fungoides or sezary syndrome cutaneous lymphoma, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a mycosis fungoides or sezary syndrome cutaneous lymphoma, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a haematologic cancer, using the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a paediatric Hodgkin lymphoma has grown and spread, using AJCC cancer staging manual (8th edition).

The stage groups that describe how far a plasma cell myeloma has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a cutaneous B cell or T cell lymphoma (non mycosis fungoides and non sezary syndrome) before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a cutaneous B cell or T cell lymphoma (non mycosis fungoides and non sezary syndrome) before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a cutaneous B cell or T cell lymphoma (non mycosis fungoides and non sezary syndrome), using the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a haematologic cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a neuroendocrine gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a neuroendocrine gastrointestinal colon and rectum tumour before initiation of treatment, using chapter 33 of the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a neuroendocrine gastrointestinal colon and rectum tumour before initiation of treatment, using chapter 33 of the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a neuroendocrine gastrointestinal colon and rectum tumour before initiation of treatment, using chapter 33 of the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a neuroendocrine gastrointestinal colon and rectum tumour before initiation of treatment, using chapter 33 of the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a neuroendocrine gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a neuroendocrine gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a neuroendocrine gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a neuroendocrine gastrointestinal cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a thoracic tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a lung tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a lung tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a lung tumour, using the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a lung cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a malignant pleural mesothelioma tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a malignant pleural mesothelioma tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a malignant pleural mesothelioma tumour, using the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a malignant pleural mesothelioma cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a thoracic tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a thoracic tumour, using the AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a thymus tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a thymus tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a thymus tumour, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a thymus cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a cervix uteri tumour before initiation of treatment, using the AJCC cancer staging manual (9th edition).

A clinical regional lymph node stage (cN) of a cervix uteri tumour before initiation of treatment, using the AJCC cancer staging manual (9th edition).

A clinical tumour stage (cT) of a cervix uteri tumour before initiation of treatment, using the AJCC cancer staging manual (9th edition).

A pathological tumour stage (pT) of a cervix uteri tumour, using the AJCC cancer staging manual (9th edition).

The stage group that describe how far a cervix uteri cancer has grown and spread, using AJCC cancer staging manual (9th edition).

A clinical distant metastasis stage (cM) of a female genital tumour before initiation of treatment, using the AJCC cancer staging manual (9th edition).

A clinical regional lymph node stage (cN) of a female genital tumour before initiation of treatment, using the AJCC cancer staging manual (9th edition).

A clinical tumour stage (cT) of a female genital tumour before initiation of treatment, using the AJCC cancer staging manual (9th edition).

A pathological distant metastasis stage (pM) of a female genital tumour, using the AJCC cancer staging manual (9th edition).

A pathological regional lymph node stage (pN) of a female genital tumour, using the AJCC cancer staging manual (9th edition).

A clinical regional lymph node stage (cN) of a vulva tumour before initiation of treatment, using the AJCC cancer staging manual (9th edition).

A pathological distant metastasis stage (pM) of a vulva tumour, using the AJCC cancer staging manual (9th edition).

A pathological regional lymph node stage (pN) of a vulva tumour, using the AJCC cancer staging manual (9th edition).

Residual tumour values on structured pathology request form (surgeon) to remove R1 - Microscopic residual tumour based on AJCC 8th edition.

A clinical distant metastasis stage (cM) of a breast tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a breast tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

The clinical stage groups that describe how far a breast cancer has grown and spread before initiation of treatment, using AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a breast tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a breast tumour, using the AJCC cancer staging manual (latest edition).

The pathological stage groups that describe how far a breast cancer has grown and spread using information obtained from pathological examination of tissue samples, using AJCC cancer staging manual (latest edition).

The anatomic and prognostic stage groups that describe how far a breast cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A numbered edition of the AJCC (AJCC)'s cancer staging system.

A clinical distant metastasis stage (cM) before initiation of treatment, using the AJCC cancer staging manual.

The clinical stage groups that describe how far a cancer has grown and spread before initiation of treatment, using AJCC cancer staging manual.

A clinical distant metastasis stage (cM) of a cervix uteri tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a cervix uteri tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a cervix uteri tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a cervix uteri tumour, using the AJCC cancer staging manual (latest edition).

The stage group that describe how far a cervix uteri cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a female genital tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a corpus uteri adenosarcoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a corpus uteri adenosarcoma, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a corpus uteri carcinoma and carcinosarcoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a corpus uteri carcinoma and carcinosarcoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a corpus uteri carcinoma and carcinosarcoma, using the AJCC cancer staging manual (latest edition).

The stage group that describe how far a corpus uteri carcinoma and carcinosarcoma has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a corpus uteri tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a corpus uteri leimyosarcoma and endometrial stromal sarcoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a corpus uteri leiomyosarcoma and endometrial stromal sarcoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a corpus uteri leiomyosarcoma and endometrial stromal sarcoma, using the AJCC cancer staging manual (latest edition).

The stage group that describe how far a corpus uteri leiomyosarcoma and endometrial stromal sarcoma has grown and spread, using AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a corpus uteri tumour, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a corpus uteri tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a corpus uteri tumour, using the AJCC cancer staging manual (latest edition).

The stage group that describe how far a corpus uteri cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a gestational trophoblastic tumour, using the AJCC cancer staging manual (latest edition).

The stage group that describe how far a gestational trophoblastic cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a ovary, fallopian tube and primary peritoneal carcinoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a ovary, fallopian tube and primary peritoneal carcinoma, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a female genital tumour, using the AJCC cancer staging manual (latest edition)..

A clinical regional lymph node stage (cN) of a vagina tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a vagina tumour, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a vagina tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a vagina tumour, using the AJCC cancer staging manual (latest edition).

The stage group that describe how far a vagina cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a vulva tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a vulva tumour, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a vulva tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a vulva tumour, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a gastrointestional tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

The pathogical stage groups that describe how far a gastrointestinal cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a gastrointestional colon and rectum tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a gastrointestional colon and rectum tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a gastrointestional colon and rectum tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a gastrointestional colon and rectum tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a gastrointestinal colon and rectum cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a gastrointestional tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A post therapy or post neoadjuvant therapy pathological tumour stage group that describe how far a gastrointestinal cancer has grown and spread, using AJCC cancer staging manual.

A clinical distant metastasis stage (cM) of a gastrointestional stromal tumour (GIST) before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a gastrointestional stromal tumour (GIST) before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a gastrointestional stromal tumour (GIST) before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a gastrointestional stromal tumour (GIST) before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a gastrointestional stromal tumour (GIST) before initiation of treatment, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a gastrointestinal stromal tumour (GIST) small intestine and oesophageal and colon and rectum and mesenteric and peritoneal has grown and spread, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a Hodgkin or non-Hodgkin lymphoma has grown and spread, using AJCC cancer staging manual (latest edition).

The stage groups that describe how far a chronic lymphocytic lymphoma or a small lymphocytic lymphoma has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a haematologic cancer before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a cutaneous B cell or T cell lymphoma (non Mycosis fungoides and non-sezary syndrome), using the AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a mycosis fungoides or sezary syndrome cutaneous lymphoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a mycosis fungoides or sezary syndrome cutaneous lymphoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a mycosis fungoides or sezary syndrome cutaneous lymphoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a mycosis fungoides or sezary syndrome cutaneous lymphoma, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a mycosis fungoides or sezary syndrome cutaneous lymphoma, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a mycosis fungoides or sezary syndrome cutaneous lymphoma, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a haematologic cancer, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a haematologic cancer, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a paediatric Hodgkin lymphoma has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a cutaneous B cell or T cell lymphoma (non Mycosis fungoides and non-sezary syndrome) before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a cutaneous B cell or T cell lymphoma (non Mycosis fungoides and non-sezary syndrome) before initiation of treatment, using the AJCC cancer staging manual (latest edition).

AJCC residual tumour (R) category.

A clinical tumour stage (cT) of a neuroendocrine gastrointestional tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a neuroendocrine gastrointestional colon and rectum tumour before initiation of treatment, the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a neuroendocrine gastrointestional colon and rectum tumour before initiation of treatment, the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a neuroendocrine gastrointestinal colon and rectum cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a neuroendocrine gastrointestional tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a neuroendocrine gastrointestional tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a neuroendocrine gastrointestinal cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM), using the AJCC cancer staging manual.

A pathological tumour stage (pT) of a tumour, using the AJCC cancer staging manual.

The pathological stage groups that describe how far a cancer has grown and spread using information obtained from pathological examination of tissue samples, using AJCC cancer staging manual.

A post therapy or post neoadjuvant therapy pathological regional lymph node stage (ypN) using the AJCC cancer staging manual.

A recurrence or retreatment clinical regional lymph node stage (rcN) before initiation of treatment, using the AJCC cancer staging manual.

A recurrence or retreatment pathological regional lymph node stage (rpN), using the AJCC cancer staging manual.

A chapter within the AJCC staging manual, used to populate TNM staging values.

A clinical regional lymph node stage (cN) of a thoracic tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a thoracic tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a lung tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a lung tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a lung cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a malignant pleural mesothelioma tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a malignant pleural mesothelioma tumour, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a malignant pleural mesothelioma tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a malignant pleural mesothelioma tumour, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a malignant pleural mesothelioma cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a thoracic tumour, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a thoracic cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a thymus tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a thymus tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a thymus tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a thymus tumour, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a thymus cancer has grown and spread, using AJCC cancer staging manual (latest edition).

The grade of a breast cancer, assessed using the Nottingham combined grading system.

The performance status of a patient as defined by the Eastern Cooperative Oncology Group (ECOG) minus ECOG 5 (A performance status used when a patient is "Dead").

A diagnosis of whether or not a tumour is progesterone receptive (PR) minus inconculsive value.

Types of responses to an acute myeloid leukaemia systemic anti-cancer therapy (SACT) treament.

Types of responses to an amyloidosis systemic anti-cancer therapy (SACT) treatment.

The type of primary cancer being assessed, by medical oncology and heamatology services

Types of responses to a chronic lymphocytic leukaemia and small lymphocytic lymphoma systemic anti-cancer therapy (SACT) treatment.

Types of responses to a chronic myeloid leukaemia systemic anti-cancer therapy (SACT) treatment.

Dose forms in which a systemic anti-cancer therapy (SACT) medication may be prescribed or administered.

Units that may be used to describe the dose of a systemic anti-cancer therapy (SACT) medication.

Types of responses to a haematological systemic anti-cancer therapy (SACT) treatment.

Types of responses to a heamatological systemic anti-cancer therapy (SACT) treatment.

Types of responses to a non small lymphocytic systemic anti-cancer therapy (SACT) treatment.

Types of responses to a medical oncology systemic anti-cancer therapy (SACT) treatment.

Types of responses to a myelodysplastic syndrome systemic anti-cancer therapy (SACT) treatment.

Overall reasons that a systemic anti-cancer therapy (SACT) regimen may be discontinued plus other value.

Patient factors that may result in the discontinuation of a systemic anti-cancer therapy (SACT) treatment plus not asked value.

TNM stage classification used to define timing of staging.

The suffix added to the TNM category.

The grade of a cancer, assessed using the WHO Classification of Tumours (5th edition) malignant differentiation grading system.

The grade of a cancer, assessed using the WHO Classification of Tumours (5th edition) malignant low / high (differentiation) grading system.

The grade of a cancer, assessed using the WHO Classification of Tumours (5th edition) atypical or typical neuroendocrine tumour grading system for thoracic tumours.

Histologies used for anal primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 7. Tumours of the anal canal,12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) excluding benign neoplasms or an 'Other' value.

Histologies used for appendix neoplasms (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 5. Tumours of the appendix,11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system or an 'Other' value.

Histologies used for bone haematolymphoid cancer types (WHO Classification of Tumours, Soft Tissue & Bone Tumours, latest edition - 4. Bone tumours) or an 'Other' value.

Histologies used for bone cancer types (WHO Classification of Tumours, Soft Tissue & Bone Tumours, latest edition - 4. Bone tumours) or an 'Other' value.

Histologies used for bone cancer types (WHO Classification of Tumours, Soft Tissue & Bone Tumours, 5th edition - 4. Bone tumours) or an 'Other' value.

Histologies used for brain primaries, from WHO Classification of Tumours, Central Nervous System Tumours (latest edition) - 2. Gliomas, glioneuronal tumours, and neuronal tumours, 3. Choroid plexus tumours, 4. Embyronal tumours, 5. Pineal tumours, 7. Meningioma, 8. Mesenchymal, non-meningothelial tumours involving the CNS, 9. Melanocytic tumours, 11. Germ cell tumours, 12. Tumours of the sellar region or an 'Other' value.

Histologies used for brain sites, from WHO Classification of Tumours, Central Nervous System Tumours (latest edition) - 2. Gliomas, glioneuronal tumours, and neuronal tumours, 3. Choroid plexus tumours, 4. Embyronal tumours, 5. Pineal tumours, 7. Meningioma, 8. Mesenchymal, non-meningothelial tumours involving the CNS, 9. Melanocytic tumours, 10. Haematolymphoid tumours involving the CNS, 11. Germ cell tumours, 12. Tumours of the sellar region or an 'Other' value.

Histologies used for behaviour free breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition) or an 'Other' value.

Histologies used for benign breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition) or an 'Other' value.

Histologies used for in situ carcinoma breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition) or an 'Other' value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition - 6. Haematolymphoid tumours of the breast) or an 'Other' value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition - 6. Haematolymphoid tumours of the breast) or an 'Other' value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition) or an 'Other' value.

Histologies used for invasive carcinoma breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition) or an 'Other' value.

Histologies used for invasive breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition) or an 'Other' value.

Histologies used for breast primaries (excluding benign), from WHO Classification of Tumours, Breast Tumours (latest edition) - Sections 2. Epithelial tumours of the breast, 3. Fibroepithelial tumours and hamartomas of the breast, 4. Tumours of the nipple, 5. Mesenchymal tumours of the breast, 7. Tumours of the male breast or an 'Other' value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition - 4. Tumours of the nipple) or an 'Other' value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition - 4. Tumours of the nipple) or an 'Other' value.

Histologies used for uncertain and borderline breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition) or an 'Other' value.

Histologies used for central nervous system cancer types (WHO Classification of Tumours, Central Nervous System Tumours, 5th edition - 3. Choroid plexus tumours) or an 'Other' value.

Histologies used for central nervous system cancer types (WHO Classification of Tumours, Central Nervous System Tumours, latest edition - 6. Cranial and paraspinal nerve tumours) or an 'Other' value.

Histologies used for central nervous system cancer types (WHO Classification of Tumours, Central Nervous System Tumours, 5th edition - 6. Cranial and paraspinal nerve tumours) or an 'Other' value.

Histologies used for central nervous system cancer types (WHO Classification of Tumours, Central Nervous System Tumours, 5th edition - 4. Embryonal tumours) or an 'Other' value.

Histologies used for central nervous system cancer types (WHO Classification of Tumours, Central Nervous System Tumours, 5th edition - 11. Germ cell tumours) or an 'Other' value.

Histologies used for central nervous system cancer types (WHO Classification of Tumours, Central Nervous System Tumours, 5th edition - 2. Gliomas, glioneuronal tumours, and neuronal tumours) or an 'Other' value.

Histologies used for central nervous system cancer types (WHO Classification of Tumours, Central Nervous System Tumours, latest edition - 10. Haematolymphoid tumours involving the CNS) or an 'Other' value.

Histologies used for central nervous system cancer types (WHO Classification of Tumours, Central Nervous System Tumours, 5th edition - 10. Haematolymphoid tumours involving the CNS) or an 'Other' value.

Histologies used for central nervous system cancer types (WHO Classification of Tumours, Central Nervous System Tumours, latest edition - 9. Melanocytic tumours) or an 'Other' value.

Histologies used for central nervous system cancer types (WHO Classification of Tumours, Central Nervous System Tumours, latest edition - 7. Meningioma) or an 'Other' value.

Histologies used for central nervous system cancer types (WHO Classification of Tumours, Central Nervous System Tumours, latest edition - 5. Pineal tumours) or an 'Other' value.

Histologies used for central nervous system cancer types (WHO Classification of Tumours, Central Nervous System Tumours, 5th edition - 5. Pineal tumours) or an 'Other' value.

Histologies used for central nervous system cancer types (WHO Classification of Tumours, Central Nervous System Tumours, latest edition - 12. Tumours of the sellar region) or an 'Other' value.

Histologies used for central nervous system cancer types (WHO Classification of Tumours, Central Nervous System Tumours, 5th edition - 12. Tumours of the sellar region) or an 'Other' value.

The grade of a cancer, assessed using the WHO Classification of Tumours central nervous system tumour grading system.

Histologies used for skin melanocytic cancer types (WHO Classification of Tumours, Skin Tumours, Chapter 3: Melanocytic neoplasms, section Ocular and CNS melanocytic tumours, latest edition, excluding Ocular and benign neoplasms) or an 'Other' value.

Histologies used for skin cancer types (WHO Classification of Tumours, Skin Tumours, latest edition, Chapter 2: keratinocytic/epidermal tumours, section Merkel cell carcinoma) or an 'Other' value.

Histologies used for skin melanocytic cancer types (WHO Classification of Tumours, Skin Tumours, Chapter 3: Melanocytic neoplasms, latest edition, excluding benign neoplasms) or an 'Other' value.

Histologies used for skin cancer types (WHO Classification of Tumours, Skin Tumours, latest edition, Chapter 2: keratinocytic/epidermal tumours, section squamous cell carcinoma) or an 'Other' value.

Histologies used for skin melanocytic cancer types (WHO Classification of Tumours, Skin Tumours, Chapter 3: Melanocytic neoplasms, section Ocular and CNS melanocytic tumours, 5th edition, excluding Ocular and benign neoplasms) or an 'Other' value.

Histologies used for skin cancer types (WHO Classification of Tumours, Skin Tumours, 5th edition, Chapter 2: keratinocytic/epidermal tumours, section Merkel cell carcinoma) or an 'Other' value.

Histologies used for intestinal T-cell and natural killer cell lymphoid proliferation (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for secondary myeloid proliferations and neoplasms (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for head and neck benign cancer types (WHO Classification of Tumours, Head and Neck Tumours, 5th edition) or an 'Other' value.

Histologies used for head and neck cancer types, ear tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 8: Ear tumours, 5th edition) or an 'Other' value.

Histologies used for head and neck cancer types, haematolymphoid proliferations and neoplasia (WHO Classification of Tumours, Head and Neck Tumours, Chapter 10: Haematolymphoid proliferations and neoplasia, 5th edition) or an 'Other' value.

Histologies used for head and neck cancer types (WHO Classification of Tumours, Head and Neck Tumours, 5th edition) or an 'Other' value.

Histologies used for head and neck cancer types, hypopharyngeal, laryngeal, tracheal, and parapharyngeal tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 3: Hypopharyngeal, laryngeal, tracheal, and parapharyngeal tumours, 5th edition) or an 'Other' value.

Histologies used for head and neck malignant cancer types (WHO Classification of Tumours, Head and Neck Tumours, 5th edition) or an 'Other' value.

Histologies used for head and neck cancer types, melanocytic tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 11: Melanocytic tumours, 5th edition) or an 'Other' value.

Histologies used for head and neck cancer types, nasal, paranasal, and skull base tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 1: Nasal, paranasal, and skull base tumours, 5th edition) or an 'Other' value.

Histologies used for head and neck cancer types, nasopharyngeal tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 2: Nasopharyngeal tumours, 5th edition) or an 'Other' value.

Histologies used for head and neck cancer types, odontogenic and maxillofacial bone tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 7: Odontogenic and maxillofacial bone tumours, 5th edition) or an 'Other' value.

Histologies used for head and neck cancer types, oral cavity and mobile tongue tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 5: Oral cavity and mobile tongue tumours, 5th edition) or an 'Other' value.

Histologies used for head and neck precursor cancer types (WHO Classification of Tumours, Head and Neck Tumours, 5th edition) or an 'Other' value.

Histologies used for head and neck cancer types, salivary gland tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 4: Salivary gland tumours, 5th edition) or an 'Other' value.

Histologies used for head and neck cancer types, soft tissue tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 9: Soft tissue tumours, 5th edition) or an 'Other' value.

Histologies used for head and neck cancer types, tumours and tumour-like lesions of the neck and lymph nodes (WHO Classification of Tumours, Head and Neck Tumours, Chapter 12: Tumours and tumour-like lesions of the neck and lymph nodes, 5th edition) or an 'Other' value.

Histologies used for skin melanocytic cancer types (WHO Classification of Tumours, Skin Tumours, Chapter 3: Melanocytic neoplasms, 5th edition, excluding benign neoplasms) or an 'Other' value.

Histologies used for skin melanocytic cancer types (WHO Classification of Tumours, Skin Tumours, Chapter 3: Melanocytic neoplasms, section Mucosal melanomas, 5th edition, excluding benign neoplasms) or an 'Other' value.

Histologies used for skin haematolymphoid cancer types (WHO Classification of Tumours, Skin Tumours, Chapter 6: Tumours of haematopoietic and lymphoid origin, 5th edition) or an 'Other' value.

Histologies used for skin cancer types (WHO Classification of Tumours, Skin Tumours, 5th edition) or an 'Other' value.

Histologies used for skin keratinocytic and epidermal cancer types (WHO Classification of Tumours, Skin Tumours, Chapter 2: keratinocytic/epidermal tumours, 5th edition) or an 'Other' value.

Histologies used for skin precursor cancer types (WHO Classification of Tumours, Skin Tumours, 5th edition) or an 'Other' value.

Histologies used for skin soft tissue cancer types (WHO Classification of Tumours, Skin Tumours, Chapter 7: Soft tissue tumours 5th edition) or an 'Other' value.

Histologies used for intestinal T-cell and natural killer cell lymphoid proliferation (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for secondary myeloid proliferations and neoplasms (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for head and neck benign cancer types (WHO Classification of Tumours, Head and Neck Tumours) or an 'Other' value.

Histologies used for head and neck cancer types, ear tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 8: Ear tumours, ) or an 'Other' value.

Histologies used for head and neck cancer types, germ cell tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 13: Germ cell tumours, ) or an 'Other' value.

Histologies used for head and neck cancer types, haematolymphoid proliferations and neoplasia (WHO Classification of Tumours, Head and Neck Tumours, Chapter 10: Haematolymphoid proliferations and neoplasia, ) or an 'Other' value.

Histologies used for head and neck cancer types, hypopharyngeal, laryngeal, tracheal, and parapharyngeal tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 3: Hypopharyngeal, laryngeal, tracheal, and parapharyngeal tumours, ) or an 'Other' value.

Histologies used for head and neck cancer types, hypopharyngeal, laryngeal, tracheal, and parapharyngeal tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 3: Hypopharyngeal, laryngeal, tracheal, and parapharyngeal tumours, Chapter 9: Soft tissue tumours, Chapter 13: Germ cell tumours, Chapter 15: Neuroendocrine neoplasms and paraganglioma, Chapter 11: Melanocytic tumours, Chapter 12: Tumours and tumour-like lesions of the neck and lymph nodes excluding benign neoplasms ) or an 'Other' value.

Histologies used for head and neck cancer types, hypopharyngeal, laryngeal, tracheal, and parapharyngeal tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 3: Hypopharyngeal, laryngeal, tracheal, and parapharyngeal tumours, Chapter 9: Soft tissue tumours, Chapter 10: Haematolymphoid proliferations and neoplasia, Chapter 13: Germ cell tumours, Chapter 15: Neuroendocrine neoplasms and paraganglioma, Chapter 11: Melanocytic tumours, Chapter 12: Tumours and tumour-like lesions of the neck and lymph nodes ) or an 'Other' value.

Histologies used for head and neck malignant cancer types (WHO Classification of Tumours, Head and Neck Tumours) or an 'Other' value.

Histologies used for head and neck cancer types, melanocytic tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 11: Melanocytic tumours, ) or an 'Other' value.

Histologies used for head and neck cancer types, nasal, paranasal, and skull base tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 1: Nasal, paranasal, and skull base tumours, ) or an 'Other' value.

Histologies used for head and neck cancer types, nasal, paranasal, and skull base tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 1: Nasal, paranasal, and skull base tumours, Chapter 9: Soft tissue tumours, Chapter 11: Melanocytic tumours, Chapter 13: Germ cell tumours, Chapter 15: Neuroendocrine neoplasms and paraganglioma excluding benign neoplasms) or an 'Other' value.

Histologies used for head and neck cancer types, nasal, paranasal, and skull base tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 1: Nasal, paranasal, and skull base tumours, Chapter 9: Soft tissue tumours, Chapter 10: Haematolymphoid proliferations and neoplasia, Chapter 11: Melanocytic tumours, Chapter 13: Germ cell tumours, Chapter 15: Neuroendocrine neoplasms and paraganglioma ) or an 'Other' value.

Histologies used for head and neck cancer types, nasal, paranasal, and skull base tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 1: Nasal, paranasal, and skull base tumours, Chapter 2: Nasopharyngeal tumours, Chapter 9: Soft tissue tumours, Chapter 11: Melanocytic tumours, Chapter 12: Tumours and tumour-like lesions of the neck and lymph nodes, Chapter 13: Germ cell tumours, Chapter 15: Neuroendocrine neoplasms and paraganglioma excluding benign neoplasms) or an 'Other' value.

Histologies used for head and neck cancer types, nasal, paranasal, and skull base tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 1: Nasal, paranasal, and skull base tumours, Chapter 2: Nasopharyngeal tumours, Chapter 9: Soft tissue tumours, Chapter 10: Haematolymphoid proliferations and neoplasia, Chapter 11: Melanocytic tumours, Chapter 13: Germ cell tumours, Chapter 15: Neuroendocrine neoplasms and paraganglioma, Chapter 12: Tumours and tumour-like lesions of the neck and lymph nodes ) or an 'Other' value.

Histologies used for head and neck cancer types, nasopharyngeal tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 2: Nasopharyngeal tumours, ) or an 'Other' value.

Histologies used for head and neck cancer types, nasopharyngeal tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 2: Nasopharyngeal tumours, Chapter 9: Soft tissue tumours, Chapter 10: Haematolymphoid proliferations and neoplasia, Chapter 13: Germ cell tumours, Chapter 15: Neuroendocrine neoplasms and paraganglioma, Chapter 11: Melanocytic tumours, Chapter 12: Tumours and tumour-like lesions of the neck and lymph nodes ) or an 'Other' value.

Histologies used for head and neck cancer types, neuroendocrine neoplasms and paraganglioma (WHO Classification of Tumours, Head and Neck Tumours, Chapter 15: Neuroendocrine neoplasms and paraganglioma, ) or an 'Other' value.

Histologies used for head and neck cancer types, odontogenic and maxillofacial bone tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 7: Odontogenic and maxillofacial bone tumours, ) or an 'Other' value.

Histologies used for head and neck cancer types, odontogenic and maxillofacial bone tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 7: Odontogenic and maxillofacial bone tumours, Chapter 9: Soft tissue tumours, & Chapter 15: Neuroendocrine neoplasms and paraganglioma excluding benign neoplasms excluding benign neoplasms) or an 'Other' value.

Histologies used for head and neck cancer types, oral cavity and mobile tongue tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 5: Oral cavity and mobile tongue tumours, ) or an 'Other' value.

Histologies used for head and neck cancer types, oral cavity and mobile tongue tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 5: Oral cavity and mobile tongue tumours, Chapter 9: Soft tissue tumours Chapter 11: Melanocytic tumours, Chapter 13: Germ cell tumours, Chapter 15: Neuroendocrine neoplasms and paraganglioma excluding benign neoplasms ) or an 'Other' value.

Histologies used for head and neck cancer types, oropharyngeal tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 6: Oropharyngeal tumours, ) or an 'Other' value.

Histologies used for head and neck cancer types, oropharyngeal tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 6: Oropharyngeal tumours, Chapter 9: Soft tissue tumours, Chapter 13: Germ cell tumours, Chapter 15: Neuroendocrine neoplasms and paraganglioma, Chapter 11: Melanocytic tumours, Chapter 12: Tumours and tumour-like lesions of the neck and lymph nodes excluding benign neoplasms) or an 'Other' value.

Histologies used for head and neck cancer types, hypopharyngeal, laryngeal, tracheal, and parapharyngeal tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 3: Hypopharyngeal, laryngeal, tracheal, and parapharyngeal tumours, Chapter 2: Nasopharyngeal tumours, Chapter 6: Oropharyngeal tumours, Chapter 9: Soft tissue tumours, Chapter 13: Germ cell tumours, Chapter 15: Neuroendocrine neoplasms and paraganglioma, Chapter 11: Melanocytic tumours, Chapter 12: Tumours and tumour-like lesions of the neck and lymph nodes excluding benign neoplasms) or an 'Other' value.

Histologies used for head and neck cancer types, hypopharyngeal, laryngeal, tracheal, and parapharyngeal tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 3: Hypopharyngeal, laryngeal, tracheal, and parapharyngeal tumours, Chapter 2: Nasopharyngeal tumours, Chapter 6: Oropharyngeal tumours, Chapter 9: Soft tissue tumours, Chapter 10: Haematolymphoid proliferations and neoplasia, Chapter 13: Germ cell tumours, Chapter 15: Neuroendocrine neoplasms and paraganglioma, Chapter 11: Melanocytic tumours, Chapter 12: Tumours and tumour-like lesions of the neck and lymph nodes) or an 'Other' value.

Histologies used for head and neck cancer types, salivary gland tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 4: Salivary gland tumours, ) or an 'Other' value.

Histologies used for head and neck cancer types, salivary gland tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 4: Salivary gland tumours,Chapter 9: Soft tissue tumours, Chapter 11: Melanocytic tumours, Chapter 13: Germ cell tumours, Chapter 15: Neuroendocrine neoplasms and paraganglioma excluding benign neoplasms) or an 'Other' value.

Histologies used for head and neck cancer types, salivary gland tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 4: Salivary gland tumours, Chapter 9: Soft tissue tumours, Chapter 10: Haematolymphoid proliferations and neoplasia, Chapter 11: Melanocytic tumours, Chapter 13: Germ cell tumours, Chapter 15: Neuroendocrine neoplasms and paraganglioma or an 'Other' value.

Histologies used for head and neck cancer types, soft tissue tumours (WHO Classification of Tumours, Head and Neck Tumours, Chapter 9: Soft tissue tumours, ) or an 'Other' value.

Histologies used for head and neck uncertain behaviour cancer types (WHO Classification of Tumours, Head and Neck Tumours) or an 'Other' value.

Histologies used for skin haematolymphoid cancer types (WHO Classification of Tumours, Skin Tumours, Chapter 6: Tumours of haematopoietic and lymphoid origin, latest edition) or an 'Other' value.

Histologies used for skin keratinocytic and epidermal cancer types (WHO Classification of Tumours, Skin Tumours, Chapter 2: keratinocytic/epidermal tumours, latest edition) or an 'Other' value.

Histologies used for skin cancer malignant types (WHO Classification of Tumours, Skin Tumours, latest edition) or an 'Other' value.

Histologies used for skin melanocytic cancer types (WHO Classification of Tumours, Skin Tumours, Chapter 3: Melanocytic neoplasms, latest edition) or an 'Other' value.

Histologies used for skin precursor cancer types (WHO Classification of Tumours, Skin Tumours, , latest edition ) or an 'Other' value.

Histologies used for colorectal primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 6. Tumours of the colon and rectum, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) excluding benign neoplasms or an 'Other' value.

Histologies used for colorectal neoplasms (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 6. Tumours of the colon and rectum, 11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an 'Other' value.

Histologies used for conjunctiva primaries, from WHO Classification of Tumours, Eye and Orbit Tumours (latest edition) - 2. Tumours of the conjunctiva and caruncle, 11. Soft tissue and bone tumours or an 'Other' value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 7. Tumours of the anal canal or an 'Other' value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, latest edition) 5. Tumours of the appendix or an 'Other' value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 5. Tumours of the appendix or an 'Other' value.

Histologies used for digestive system benign cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) or an 'Other' value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, latest edition) 6. Tumours of the colon and rectum or an 'Other' value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 6. Tumours of the colon and rectum. Neuroendocrine tumour hormone producing subtype or an 'Other' value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 13. Other digestive system, germ cell tumour or an 'Other' value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 11. Haematolymphoid tumours of the digestive system or an 'Other' value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 8. Tumours of the liver and intrahepatic bile ducts or an 'Other' value.

Histologies used for digestive system malignant cancer types (WHO Classification of Tumours, Digestive System Tumours) or an 'Other' value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, latest edition) 12. Mesenchymal tumours of the digestive system or an 'Other' value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 12. Mesenchymal tumours of the digestive system or an 'Other' value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, latest edition) 2. Tumours of the oesophagus or an 'Other' value.

Histologies used for digestive system precursor cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) or an 'Other' value.

Histologies used for digestive system uncertani behaviour cancer types (WHO Classification of Tumours, Digestive System Tumours) or an 'Other' value.

Histologies used for digestive system uncertani behaviour cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 5. Adrenal gland tumours 9. Mesenchymal and stromal tumours and 11. Germ cell tumours excluding benign neoplasms or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 5. Adrenal gland tumours 9. Mesenchymal and stromal tumours, 10. Haematolymphoid tumours and 11. Germ cell tumours .or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 5. Adrenal gland tumours or an 'Other' value.

Histologies used for endocrine and neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, 5th edition) 5. Adrenal gland tumours or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 5. Adrenal gland tumours, 6. Adrenal medulla and extra-adrenal paraganglia tumours 9. Mesenchymal and stromal tumours and 11. Germ cell tumours excluding benign neoplasms or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition)5. Adrenal gland tumours, 6. Adrenal medulla and extra-adrenal paraganglia tumours 9. Mesenchymal and stromal tumours, 10. Haematolymphoid tumours and 11. Germ cell tumours or an 'Other' value.

Histologies used for endocrine and Neuroendocrine adrenal medulla cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 6. Adrenal medulla and extra-adrenal paraganglia tumours (excluding paraganglioma) 8. Neuroendocrine neoplasms in non-endocrine organs excluding benign neoplasms or an 'Other' value.

Histologies used for endocrine and neuroendocrine benign cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, 5th edition) or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 11. Germ cell tumours or an 'Other' value.

Histologies used for endocrine and neuroendocrine malignant cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours) or an 'Other' value.

Histologies used for endocrine and neuroendocrine malignant cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, 5th edition) or an 'Other' value.

Histologies used for endocrine and Neuroendocrine adrenal medulla cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 6. Adrenal medulla and extra-adrenal paraganglia tumours (Paraganglioma and Composite paraganglion tumours). 8. Neuroendocrine neoplasms in non-endocrine organs (Paraganglioma-like neuroendocrine neoplasms) excluding benign neoplasms or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 4. Parathyroid tumours 9. Mesenchymal and stromal tumours and 11. Germ cell tumours excluding benign neoplasms or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 4. Parathyroid tumours 9. Mesenchymal and stromal tumours, 10. Haematolymphoid tumours and 11. Germ cell tumours or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 2. Pituitary tumours or an 'Other' value.

Histologies used for endocrine and neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, 5th edition) 2. Pituitary tumours or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 2. Pituitary tumours value, 9. Mesenchymal and stromal tumours, 10. Haematolymphoid tumours, 11: Germ cell tumours excluding benign neoplasms or an 'Other'.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 3. Thyroid tumours or an 'Other' value.

Histologies used for endocrine and neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, 5th edition) 3. Thyroid tumours or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) including sections 3. Thyroid tumours, 9. Mesenchymal and stromal tumours, 11. Germ cell tumours benign neoplasms, or an 'Other' value.

Histologies used for endocrine and neuroendocrine uncertain behaviour cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours) or an 'Other' value.

Histologies used for endocrine and neuroendocrine uncertain behaviour cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, 5th edition) or an 'Other' value.

Histologies used for endocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 2.pituitary tumours, 3. Thyroid tumours, 4. Parathyroid tumours, 5. Adrenal gland tumours, 6. Adrenal medulla and extra-adrenal paraganglia tumours, 9. Mesenchymal and stromal tumours, 11: Germ cell tumours excluding benign neoplasms or an 'Other' value.

Histologies used for behaviour free eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, latest edition) or an 'Other' value.

Histologies used for eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, latest edition - 3. Tumours of the eyelid) or an 'Other' value.

Histologies used for eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, latest edition - 10. Haematolymphoid tumours) or an 'Other' value.

Histologies used for eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, 5th edition - 10. Haematolymphoid tumours) or an 'Other' value.

Histologies used for eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, 5th edition) or an 'Other' value.

Histologies used for in situ eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, latest edition) or an 'Other' value.

Histologies used for eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, latest edition - 7. Tumours of the lacrimal gland) or an 'Other' value.

Histologies used for eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, 5th edition - 7. Tumours of the lacrimal gland) or an 'Other' value.

Histologies used for eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, latest edition - 6. Tumours of the optic disc and optic nerve) or an 'Other' value.

Histologies used for eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, 5th edition - 6. Tumours of the optic disc and optic nerve) or an 'Other' value.

Histologies used for eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, 5th edition - 5. Tumours of the retina and neuroepithelium) or an 'Other' value.

Histologies used for eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, 5th edition - 11. Soft tissue and bone tumours) or an 'Other' value.

Histologies used for uncertain and borderline eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, 5th edition) or an 'Other' value.

Histologies used for eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, latest edition - 4. Tumours of the uveal tract) or an 'Other' value.

Histologies used for eyelid sites, from WHO Classification of Tumours, Eye and Orbit Tumours (latest edition) - 3. Tumours of the eyelid, 10. Haematolymphoid tumours, 11. Soft tissue and bone tumours or an 'Other' value.

Histologies used for fallopian tube primaries, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 5. Tumours of the fallopian tube, 12. Neuroendocrine neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions, Endometriosis or an 'Other' value.

Histologies used for female breast primaries, except for the nipple (excluding benign), from WHO Classification of Tumours, Breast Tumours (latest edition) - Sections 2. Epithelial tumours of the breast, 3. Fibroepithelial tumours and hamartomas of the breast, 5. Mesenchymal tumours of the breast or an 'Other' value.

Histologies used for female genital germ cell tumours (WHO Classification of Tumours, Female Genital Tumours, 5th edition) or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 8. Gestational trophoblastic disease) or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 13. Haematolymphoid proliferations and neoplasia) or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition - 13. Haematolymphoid proliferations and neoplasia) or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition) or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 15. Melanocytic lesions) or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 14. Mesenchymal tumours of lower genital tract) or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 12. Neuroendocrine neoplasia) or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition - 12. Neuroendocrine neoplasia) or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 2. Tumours of the ovary) or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition - 2. Tumours of the ovary) or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 4. Tumours of the peritoneum) or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition - 4. Tumours of the peritoneum) or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 6. Tumours of the broad ligament and other uterine ligaments or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 10. Tumours of the vagina) or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition - 10. Tumours of the vagina) or an 'Other' value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 11. Tumours of the vulva) or an 'Other' value.

Histologies used for gestational trophoblastic sites, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 8. Gestational trophoblastic disease, 12. Neuroendocrine neoplasia, 13. Haematolymphoid proliferations and neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an 'Other' value.

Histologies used for chronic myeloproliferative neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for chronic myeloproliferative neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours, 5th editions) or an 'Other' value.

Histologies used for B-cell lymphoid neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours) which are not Castleman disease, Acute lymphoblastic leukaemia, Indolent non-Hodgkin B cell lymphoma, Aggressive non-Hodgkin B cell lymphoma, Hodgkin lymphoma or Plasma cell disorders or an 'Other' value.

Histologies used for B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition)

Histologies used for B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition)

Histologies used for B lymphoblastic leukaemia lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for Burkitt lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for Burkitt lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for Castleman disease (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for Castleman disease (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for t lymphoblastic leukemia (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for T-cell and natural killer cell neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours latest edition) or an 'Other' value.

Histologies used for acute leukaemia of mixed or ambiguous lineage (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for acute lymphoblastic leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for aggressive B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for aggressive non-Hodgkin B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for aggressive non-hodgkin B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for amyloidosis (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for chronic leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition)

Histologies used for chronic lymphocytic leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition)

Histologies used for chronic lymphocytic leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition)

Histologies used for chronic myeloid leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for chronic myelomonocytic leukemia (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for chronic neutrophilic leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for essential thrombocythemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for essential thrombocythemia (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for Epstein-Barr virus positive T-cell and natural killer cell lymphoiod proliferation (WHO Classification of Tumours, Haematolymphoid Tumours,latest edition) or an 'Other' value.

Histologies used for extranodal NK cell and T cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for extranodal NK cell and T cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for hairy cell leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for histiocytic and dendritic cell neoplasms (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition - 3. Histiocytic/Dendritic cell neoplasms) or an 'Other' value.

Histologies used for histiocytic and dendritic cell neoplasms not dendritic cell or blastic plasmacytoid dendritic cell (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for indolent B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for indolent B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for other indolent B cell lymphoma not Chronic lymphocytic leukaemia and small lymphocytic lymphoma, Monoclonal B cell lymphocytosis, Hairy cell leukaemia, Lymphoplasmacytic lymphoma (Waldenstrom macroglobulinaemia), Marginal zone lymphoma or Follicular lymphoma or Mantle cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for indolent non-Hodgkin B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for other indolent non-hodgkin B cell lymphoma not Chronic lymphocytic leukaemia and/or small lymphocytic lymphoma, Monoclonal B cell lymphocytosis, Hairy cell leukaemia, Lymphoplasmacytic lymphoma (Waldenstrom macroglobulinaemia), Marginal zone lymphoma or Follicular lymphoma Mantle cell lymphoma(WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition)

Histologies used for leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition)

Histologies used for lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) excluding samll lymphocytic disease or an 'Other' value.

Histologies used for lymphoplasmacytic lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for lymphoplasmacytic lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for mantle cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for mantle cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for marginal zone lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for mast cell sarcoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for mastocytosis which are not systemic or cutaneous or mast cell sarcoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for mature T cell and natural killer cell leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for mature T cell and natural killer cell leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for mature T cell and natural killer cell neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for mature T-cell and natural killer cell neoplasm not peripheral T cell or extranodal NK/T cell or primary T cell cutaneous lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours latest edition) or an 'Other' value.

Histologies used for monoclonal B-cell lymphocytosis (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for myelodysplastic and myeloproliferative neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for myelodysplastic and myeloproliferative neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for myelodysplastic and myeloproliferative neoplasm not chronic myelomonocytic leukemia (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for myelodysplastic syndrome (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for myelodysplastic syndrome (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for other myeloid proliferations and neoplasms (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for myeloid/lymphoid neoplasm with eosinophilia and defining gene rearrangement (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for myeloma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for myeloproliferative neoplasm which are not primary myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukaemia, chronic eosinophilic leukaemia, juvenile myelomonocytic leukaemia, (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for non Hodgkin lymphoma (WHO Classification of tumours, Haematolymphoid Tumours, 5th edition)

Histologies used for peripheral T cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for plasma cell neoplasms and other diseases with paraprotiens that are not amyloidosis or multiple myeloma (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for plasma cell neoplasms and other diseases with paraproteins (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for plasmacytoid dendritic cell neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for polycythemia vera (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for primary central nervous system lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for primary cutaneous T cell lymphoproliferative disorder (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an 'Other' value.

Histologies used for primary cutaneous T cell lymphoproliferative disorder (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for reactive B-cell rich lymphoid proliferations that can mimic lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for small lymphocytic lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition)

Histologies used for systemic mastocytosis (WHO Classification of Tumours, Haematolymphoid Tumours) or an 'Other' value.

Histologies used for haematolymphoid cancer types (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an 'Other' value.

Histologies used for heart primaries (from WHO Classification of Tumours, Thoracic Tumours, latest edition, including sections 4. Tumours of the heart, 5. Mesenchymal tumours of the thorax, 7. Germ cell tumours of the mediastinum and 9. Ectopic tumours of thyroid and parathyroid origin) excluding benign neoplasms or an 'Other' value.

Histologies used for B cell lymphoid proliferations and lymphomas (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition - 4. B cell lymphoid proliferations and lymphomas) or an 'Other' value.

Histologies used for T cell and NK cell lymphoid proliferations and lymphomas (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition - 5. T cell and NK cell lymphoid proliferations and lymphomas) or an 'Other' value.

Histologies used for histiocytic and dendritic cell neoplasms (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition - 3. Histiocytic/Dendritic cell neoplasms) or an 'Other' value.

Histologies used for myeloid proliferations and neoplasms (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition - 2. Myeloid proliferations and neoplasms excluding secondary myeloid neoplasm) or an 'Other' value.

Histologies used for stroma-derived neoplasms of lymphoid tissues (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition - 6. Stroma-derived neoplasms of lymphoid tissues) or an 'Other' value.

Histologies used for any cancer type (WHO Classification of Tumours, latest editions) or an 'Other' value.

Histologies used for kidney primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 2. Tumours of the kidney, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 12. Melanocytic lesions or an 'Other' value.

Histologies used for lacrimal drainage system primaries, from WHO Classification of Tumours, Eye and Orbit Tumours (latest edition) - 8. Tumours of the lacrimal drainage system or an 'Other' value.

Histologies used for lacrimal gland primaries, from WHO Classification of Tumours, Eye and Orbit Tumours (latest edition) - 7. Tumours of the lacrimal gland, 11. Soft tissue and bone tumours or an 'Other' value.

Histologies used for lacrimal gland sites, from WHO Classification of Tumours, Eye and Orbit Tumours (latest edition) - 7. Tumours of the lacrimal gland, 10. Haematolymphoid tumours, 11. Soft tissue and bone tumours or an 'Other' value.

Histologies used for liver neoplasms (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 8. Tumours of the liver and intrahepatic bile ducts, 11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Germ cell tumours only)) or an 'Other' value.

Histologies used for lower gastrointestinal primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 5. Tumours of the appendix, 6. Tumours of the colon and rectum, 7. Tumours of the anal canal, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) excluding benign neoplasms or an 'Other' value.

Histologies used for lower gastrointestinal primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 5. Tumours of the appendix, 6. Tumours of the colon and rectum, 7. Tumours of the anal canal, 11. Haematolymphoid tumours of the digestive system 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an 'Other' value.

Histologies used for male breast primaries (excluding benign), from WHO Classification of Tumours, Breast Tumours (latest edition) - Sections 3. Fibroepithelial tumours and hamartomas of the breast, 4. Tumours of the nipple, 5. Mesenchymal tumours of the breast, 7. Tumours of the male breast or an 'Other' value.

A subset of the maximal differentiation grading reference set (excluding G4; undifferentiated grade), described by World Health Organization.

The grade of a cancer, assessed using the WHO Classification of Tumours differentiation grading system.

The grade of a cancer, assessed using the WHO Classification of Tumours low / high (differentiation) grading system.

Histologies used for any medical oncology cancer site (WHO Classification of Tumours, latest editions) or an 'Other' value.

Histologies used for meninges primaries, from WHO Classification of Tumours, Central Nervous System Tumours (latest edition) - 7. Meningioma, 8. Mesenchymal, non-meningothelial tumours involving the CNS, 9. Melanocytic tumours, 12. Tumours of the sellar region or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 8. Neuroendocrine neoplasms in non-endocrine organs or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 7. Pancreatic neuroendocrine neoplasms or an 'Other' value.

Histologies used for endocrine and neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, 5th edition) 7. Pancreatic neuroendocrine neoplasms or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 7. Pancreatic neuroendocrine neoplasms 9. Mesenchymal and stromal tumours, and 11. Germ cell tumours excluding benign neoplasms or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 7. Pancreatic neuroendocrine neoplasms, neuroendocrine tumours 8. Neuroendocrine neoplasms in non-endocrine organs neuroendocrine tumours or an 'Other' value.

The grade of a cancer, assessed using the WHO Classification of Tumours neuroendocrine tumour grading system.

Histologies used for neuroendocrine tumours (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 8. Neuroendocrine neoplasms in non-endocrine organs neuroendocrine tumours excluding benign neoplasms or an 'Other' value.

Histologies used for neuroendocrine tumours (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, 5th edition) 8. Neuroendocrine neoplasms in non-endocrine organs neuroendocrine tumours excluding benign neoplasms or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, 5th edition) 7. Pancreatic neuroendocrine neoplasms, neuroendocrine tumours or an 'Other' value.

Histologies used for oesophagus primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 2. Tumours of the oesophagus, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) excluding benign neoplasms or an 'Other' value.

Histologies used for eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, latest edition - 9. Tumours of the orbit) or an 'Other' value.

Histologies used for eye and orbit cancer types (WHO Classification of Tumours, Eye and Orbit Tumours, 5th edition - 9. Tumours of the orbit) or an 'Other' value.

Histologies used for orbit primaries, from WHO Classification of Tumours, Eye and Orbit Tumours (latest edition) - 9. Tumours of the orbit, 11. Soft tissue and bone tumours or an 'Other' value.

Histologies used for ovary primaries, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 2. Tumours of the ovary, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an 'Other' value.

Histologies used for ovary sites, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 2. Tumours of the ovary, 13. Haematolymphoid proliferations and neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions, Endometriosis or an 'Other' value.

Histologies used for pancreatic primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 10. Tumours of the pancreas,12. Mesenchymal tumours of the digestive system) excluding benign neoplasms or an 'Other' value.

Histologies used for pancreatic neoplasms (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 10. Tumours of the pancreas, 11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system) or an 'Other' value.

Histologies used for penis primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 8. Tumours of the penis and scrotum, 9. Neuroendocrine neoplasms, 12. Melanocytic lesions or an 'Other' value.

Histologies used for penis sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 8. Tumours of the penis and scrotum, 9. Neuroendocrine neoplasms, 12. Melanocytic lesions or an 'Other' value.

Histologies used for pericardium primaries (from WHO Classification of Tumours, Thoracic Tumours, latest edition, including sections 3. Tumours of the pleura and pericardium (excluding haematolymphoid tumours), 5. Mesenchymal tumours of the thorax, 7. Germ cell tumours of the mediastinum and 9. Ectopic tumours of thyroid and parathyroid origin) excluding benign neoplasms or an 'Other' value.

Histologies used for pericardium neoplasms (from WHO Classification of Tumours, Thoracic Tumours, latest edition, including sections 3. Tumours of the pleura and pericardium, 5. Mesenchymal tumours of the thorax, 7. Germ cell tumours of the mediastinum, 8. Haematolymphoid tumours of the mediastinum, and 9. Ectopic tumours of thyroid and parathyroid origin) or an 'Other' value.

Histologies used for peritoneum sites, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 4. Tumours of the peritoneum, 12. Neuroendocrine neoplasia, 13. Haematolymphoid proliferations and neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions, Endometriosis or an 'Other' value.

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, latest edition) 2. Pituitary tumours section Anterior pituitary neuroendocrine tumours (PitNETs).

Histologies used for endocrine and Neuroendocrine cancer types (WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, 5th edition) 2. Pituitary tumours section Anterior pituitary neuroendocrine tumours (PitNETs).

Histologies used for pleural neoplasms (from WHO Classification of Tumours, Thoracic Tumours, latest edition, including sections 3. Tumours of the pleura and pericardium and 5. Mesenchymal tumours of the thorax) or an 'Other' value.

Histologies used for prostate primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 4. Tumours of the prostate, 5. Tumours of the seminal vesicle, 9. Neuroendocrine neoplasms, 12. Melanocytic lesions or an 'Other' value.

Histologies used for prostate sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 4. Tumours of the prostate, 5. Tumours of the seminal vesicle, 9. Neuroendocrine neoplasms, 11. Haematolymphoid tumours, 12. Melanocytic lesions or an 'Other' value.

Histologies used for sclera primaries, from WHO Classification of Tumours, Eye and Orbit Tumours (latest edition) - 11. Soft tissue and bone tumours or an 'Other' value.

Histologies used for small intestine primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 4. Tumours of the small intestine and ampulla,, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) excluding benign neoplasms or an 'Other' value.

Histologies used for small intestine neoplasms(from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 4. Tumours of the small intestine and ampulla, 11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an 'Other' value.

Histologies used for soft tissue and bone cancer types (WHO Classification of Tumours, Soft Tissue & Bone Tumours, latest edition - 3. Undifferentiated small round cell sarcoma of bone and soft tissue) or an 'Other' value.

Histologies used for soft tissue and bone cancer types (WHO Classification of Tumours, Soft Tissue & Bone Tumours, 5th edition - 3. Undifferentiated small round cell sarcoma of bone and soft tissue) or an 'Other' value.

Histologies used for soft tissue cancer types (WHO Classification of Tumours, Soft Tissue & Bone Tumours, latest edition - 2. Soft tissue tumours) or an 'Other' value.

Histologies used for soft tissue primaries, from WHO Classification of Tumours, Soft Tissue & Bone Tumours (latest edition) - 2. Soft tissue tumours, 3. Undifferentiated small round cell sarcomas of bone and soft tissue or an 'Other' value.

Histologies used for soft tissue sites, from WHO Classification of Tumours, Soft Tissue & Bone Tumours (latest edition) - 2. Soft tissue tumours, 3. Undifferentiated small round cell sarcomas of bone and soft tissue or an 'Other' value.

Histologies used for spinal cord sites, from WHO Classification of Tumours, Central Nervous System Tumours (latest edition) - 2. Gliomas, glioneuronal tumours, and neuronal tumours, 4. Embyronal tumours, 8. Mesenchymal, non-meningothelial tumours involving the CNS, 9. Melanocytic tumours, 10. Haematolymphoid tumours involving the CNS or an 'Other' value.

Histologies used for stomach primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 3. Tumours of the stomach,12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) excluding benign neoplasms or an 'Other' value.

Histologies used for testicular adnexa primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 7. Tumours of the testicular adnexa, 9. Neuroendocrine neoplasms, 12. Melanocytic lesions or an 'Other' value.

Histologies used for testicular adnexa sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 7. Tumours of the testicular adnexa, 9. Neuroendocrine neoplasms, 11. Haematolymphoid tumours, 12. Melanocytic lesions or an 'Other' value.

Histologies used for testies primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 6. Tumours of the testis, 9. Neuroendocrine neoplasms, 12. Melanocytic lesions or an 'Other' value.

Histologies used for testies sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 6. Tumours of the testis, 9. Neuroendocrine neoplasms, 11. Haematolymphoid tumours, 12. Melanocytic lesions or an 'Other' value.

Histologies used for thoracic benign cancer types (WHO Classification of Tumours, Thoracic Tumours) or an 'Other' value.

Histologies used for thoracic benign cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) or an 'Other' value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, latest edition) 9. Ectopic tumours of thyroid and parathyroid origin or an 'Other' value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) 9. Ectopic tumours of thyroid and parathyroid origin or an 'Other' value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours) 8. Haematolymphoid tumours of the mediastinum and heamtolymphoid subsections in 2. Tumours of the lung, 3. Tumours of the pleura and pericardium and 4. Tumours of the heart or an 'Other' value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) 4. Tumours of the heart or an 'Other' value.

Histologies used for thoracic uncertain behaviour cancer types (WHO Classification of Tumours, Thoracic Tumours) or an 'Other' value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) 7. Germ cell tumours of the mediastinum or an 'Other' value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) 8. Haematolymphoid tumours of the mediastinum or an 'Other' value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, latest edition) 5. Mesenchymal tumours of the thorax or an 'Other' value.

The grade of a cancer, assessed using the WHO Classification of Tumours atypical or typical neuroendocrine tumour grading system for thoracic tumours.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, latest edition) 2. Tumours of the lung. Non small cell histology or an 'Other' value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) 2. Tumours of the lung. Non small cell histology or an 'Other' value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, latest edition) 3. Tumours of the pleura and pericardium or an 'Other' value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) 3. Tumours of the pleura and pericardium or an 'Other' value.

Histologies used for thoracic precursor cancer types (WHO Classification of Tumours, Thoracic Tumours) or an 'Other' value.

Histologies used for thoracic precursor cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) or an 'Other' value.

Histologies used for thoracic cancer types excluding heamatological histologies and benign neoplasm (WHO Classification of Tumours, Thoracic Tumours, latest edition) or an 'Other' value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, latest edition) 2. Tumours of the lung. Small cell histology or an 'Other' value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) 2. Tumours of the lung. Small cell histology or an 'Other' value.

Histologies used for upper gastrointestinal primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 2. Tumours of the oesophagus, 3. Tumours of the stomach, 4. Tumours of the small intestine and ampulla, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) excluding benign neoplasms or an 'Other' value.

Histologies used for upper gastrointestinal neoplasms (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 2. Tumours of the oesophagus, 3. Tumours of the stomach, 4. Tumours of the small intestine and ampulla, 11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an 'Other' value.

Histologies used for urethra primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 3. Tumours of the urinary tract, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 12. Melanocytic lesions or an 'Other' value.

Histologies used for urethra sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 3. Tumours of the urinary tract, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 11. Haematolymphoid tumours, 12. Melanocytic lesions or an 'Other' value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition - 11. Haematolymphoid tumours) or an 'Other' value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition) or an 'Other' value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition) or an 'Other' value.

Histologies used for germ cell tumours of kidney (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition) or an 'Other' value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 2. Tumours of the kidney) or an 'Other' value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition - 2. Tumours of the kidney) or an 'Other' value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 9. Neuroendocrine neoplasms) or an 'Other' value.

Histologies used for urinary and male genital primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 2. Tumours of the kidney, 3. Tumours of the urinary tract, 4. Tumours of the prostate, 5. Tumours of the seminal vesicle, 6. Tumours of the testis, 7. Tumours of the testicular adnexa, 8. Tumours of the penis and scrotum, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 12. Melanocytic lesions or an 'Other' value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 4. Tumours of the prostate) or an 'Other' value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition - 4. Tumours of the prostate) or an 'Other' value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 7. Tumours of the tesicular adnexa) or an 'Other' value.

Histologies used for germ cell tumours of testis (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition) or an 'Other' value.

Histologies used for germ cell tumours of testis (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition) or an 'Other' value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 6. Tumours of the testis) or an 'Other' value.

Histologies used for urinary bladder primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 3. Tumours of the urinary tract, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 12. Melanocytic lesions or an 'Other' value.

Histologies used for urinary system sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 2. Tumours of the kidney, 3. Tumours of the urinary tract, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 11. Haematolymphoid tumours, 12. Melanocytic lesions or an 'Other' value.

Histologies used for uterine corpus primaries, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 7. Tumours of the uterine corpus, 12. Neuroendocrine neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an 'Other' value.

Histologies used for uterine corpus sites, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 7. Tumours of the uterine corpus, 12. Neuroendocrine neoplasia, 13. Haematolymphoid proliferations and neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an 'Other' value.

Histologies used for uterine ligament sites, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 6. Tumours of the broad ligament and other uterine ligaments, 12. Neuroendocrine neoplasia, 13. Haematolymphoid proliferations and neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an 'Other' value.

Histologies used for uterine primaries, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 6.Tumour of the broad ligament and other uterine ligaments, 7. Tumours of the uterine corpus, 12. Neuroendocrine neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an 'Other' value.

Histologies used for uveal tract sites, from WHO Classification of Tumours, Eye and Orbit Tumours (latest edition) - 4. Tumours of the uveal tract, 10. Haematolymphoid tumours or an 'Other' value.

Histologies used for vagina sites, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 10. Tumours of the vagina, 12. Neuroendocrine neoplasia, 13. Haematolymphoid proliferations and neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an 'Other' value.

Histologies used for vulva primaries, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 11. Tumours of the vulva, 12. Neuroendocrine neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an 'Other' value.

Histologies used for vulva sites, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 11. Tumours of the vulva, 12. Neuroendocrine neoplasia, 13. Haematolymphoid proliferations and neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an 'Other' value.

The stage groups for lymphoma, defined using Ann Arbor staging system.

The type of B cell lymphoid haematologic cancer being assessed and treated.

The subcategory of B cell lymphoid haematologic cancer being assessed and treated.

The type of B cell lymphoma haematologic cancer being assessed and/or treated.

The prognostic score for Burkitt lymphoma, defined using the Burkitt Lymphoma International Prognostic Index (BL-IPI) scoring system..

The type of the primary central nervous system (CNS) solid cancer being assessed and treated.

The body location used to describe the point of origin for a CNS (central nervous system) melanoma or an 'Other' value.

The prognostic score for reporting status in acute lymphoblastic lymphoma, defined using the central nervous system (CNS) prognostic scoring system.

The prognostic score for large B-cell lymphoma, defined using the Central Nervous System International Prognostic Index (CSN-IPI) scoring system.

The prognostic score for reporting genetic alteration in acute myeloid leukaemia, defined using the European LeukemiaNet (ELN) prognostic scoring system.

An assessment of whether or not a tumour is estrogen receptive (ER).

The prognostic score for chronic myeloid leukaemia, defined using the European Treatment and Outcome Study (EUTOS) prognostic scoring system.

The stage groups for a gestational trophoblastic tumour, defined by International Federation of Gynecology and Obstetrics 2001 staging system.

The stage groups for an endometrial carcinoma, defined by International Federation of Gynecology and Obstetrics 2009 staging system.

The stage groups for a corpus uteri adenosarcoma, defined by International Federation of Gynecology and Obstetrics 2015 staging system.

The stage groups for a cervix uteri tumour, defined by International Federation of Gynecology and Obstetrics 2018 staging system.

The stage groups for a vulva tumour, defined by International Federation of Gynecology and Obstetrics 2021 staging system.

The prognostic score for follicular lymphoma, defined using the Follicular Lymphoma International Prognostic Scoring (FLIPI) system.

The stage groups for Hodgkin lymphoma, defined using German Hodgkin Study Group (GHSG) staging system.

The prognostic score for Hodgkin lymphoma, defined using the Hodgkin lymphoma International Prognostic Score (IPS) system.

The prognostic score for myelodysplastic syndrome, defined using the Revised International Prognostic Scoring System (IPSS-R).

The stage groups for lymphoma defined using the Lugano staging system.

The prognostic score for marginal zone lymphoma of mucosa associated lymphoid tissue international prognostic index (MALT-IPI) prognostic scoring system.

The neoadjuvant therapy response score for breast, defined using the MD Anderson residual cancer burden system.

The prognostic score for mantle cell lymphoma, defined using the Mantle Cell Lymphoma International Prognostic Scoring (MIPI) system.

The prognostic score for myelofibrosis, defined using the Mutation-Enhanced International Prognostic Score System (MIPSS) age seventy-plus version two prognostic scoring system.

Test method procedures used in laboratory studies.

The neoadjuvant therapy response score for solid tumours, defined using the PERCIST 1.0 cancer burden system.

The prognostic score for T-cell lymphoma, defined using the Prognostic Index for T-cell Lymphoma (PIT) prognostic scoring system.

The stage groups for multiple myeloma, defined using Revised International Staging System (R-ISS).

The neoadjuvant therapy response score for solid tumours, defined using the RECIST 1.1 cancer burden system.

The stage groups for chronic lymphocytic leukaemia, defined by Rai staging system.

The type of T/NK cell lymphoma haematologic cancer being assessed and/or treated.

The type of acute leukaemia haematologic cancer being assessed and/or treated.

The body location used to describe the point of origin for cancer of the adrenal gland excluding lymph nodes or an 'Other' value.

The type of aggressive B cell lymphoma haematologic cancer being assessed and treated.

The type of aggressive non-Hodgkin B cell lymphoma haematologic cancer being assessed and/or treated.

Types of evidence that may be used to reach a cancer diagnosis.

The type of the primary bone solid cancer being assessed and treated.

The body location used to describe the point of origin for other bone cancer or an 'Other' value.

The body location used to describe the point of origin for pelvic bone cancer or an 'Other' value.

The body location used to describe the point of origin for thoracic bone cancer or an 'Other' value.

The body location used to describe the point of origin for vertebral column cancer or an 'Other' value.

The ancillary studies relevant to breast tumours.

The behaviour categories relevant to breast tumours by clincal examination.

The relevant clinical symptoms or findings for a breast cancer or an 'Other' value.

Lymph nodes used for diagnosis of breast cancer or an 'Other' value.

The radiologic findings relevant to breast tumours by mammographic imaging, or an 'Other' value.

The body location used to describe the point of origin for non nipple-areolar complex breast cancer or an 'Other' value.

Procedure image guided methods relevant to breast, or an 'Other' or 'Not applicable' value.

Types of radiology imaging relevant to breast, or an 'Other' value.

A body location used to describe a body site in the breast or related to the breast (e.g. a lymph node) or an 'Other' value.

The resection procedure types relevant to breast specimens, or an 'Other' value.

The radiologic findings relevant to breast tumours by ultrasound imaging, or an 'Other' value.

The body location used to describe the point of origin for brain cancer or an 'Other' value.

The body location used to describe the point of origin for meninges cancer or an 'Other' value.

The body location used to describe the point of origin for nerve cancer of the central nervous system or an 'Other' value.

The body location used to describe the point of origin for other central nervous system cancer or an 'Other' value.

The body location used to describe the point of origin for central nervous system cancer or an 'Other' value.

A clinical assessment scale.

The behaviour categories relevant to clinical impression of tumour behaviour.

The clockface position values relevant when describing a tumour site.

Body sites that are accessed by a surgeon during a colonoscopy procedure or an 'Other' value.

The type of the primary colorectal solid cancer being assessed and/or treated.

Body site subtypes that are accessed by a surgeon during a colorectal metastectomy procedure or an 'Other' value.

The type of colonoscopy specimen collected for a colorectal screening pathology request.

The clinical indication(s) required for a referral into the colorectal surveillance colonoscopy pathway with the addition of other value.

A reason that no specific value is available.

The status of the primary diagnosis in terms of its clinical progression.

The specific type of document, e.g. radiotherapy care plan.

The type of the primary endocrine and neuroendocrine tumour solid cancer being assessed and treated.

The subcategory of the primary endocrine and neuroendocrine tumour solid cancer being assessed and treated.

The body location used to describe the point of origin for cancer of an endocrine organ or a cancer with a neuroendocrine histology or 'Other' value.

The body location used to describe the point of origin for cancer of an endocrine organ (excluding pancreas and lymph nodes) and which is not a thyroid, parathyroid, adrenal or pituitary primary or an 'Other' value.

The body location used to describe the point of origin for cancer of an endocrine organ, excluding pancreas and lymph nodes or an 'Other' value.

The type of excision specimen collected for a pathology request or an 'Other' value.

The type of primary eye and/or orbit solid cancer being assessed and treated.

The body location used to describe the point of origin for lacrimal drainage system cancer or an 'Other' value.

The body location used to describe the point of origin for lacrimal gland cancer or an 'Other' value.

Lymph nodes used for diagnosis of eye and orbit cancer or an 'Other' value.

The body location used to describe the point of origin for optic nerve cancer or an 'Other' value.

The body location used to describe the point of origin for other eye and orbit cancer or an 'Other' value.

The body location used to describe the point of origin for uveal tract cancer or an 'Other' value.

Lymph nodes used for diagnosis of cervix uteri cancer or an 'Other' value.

The body location used to describe the point of origin for cervix uteri cancer or an 'Other' value.

Lymph nodes used for diagnosis of corpus uteri cancer or an 'Other' value.

The body location used to describe the point of origin for corpus uteri cancer or an 'Other' value.

The body location used to describe the point of origin for fallopian tube cancer or an 'Other' value.

The body location used to describe the point of origin for gestational trophoblastic disease cancer or an 'Other' value.

The body location used to describe the point of origin for peritoneum cancer or an 'Other' value.

The body location used to describe the point of origin for uterine ligament cancer or an 'Other' value.

Lymph nodes used for diagnosis of vulva cancer or an 'Other' value.

The body location used to describe the point of origin for vulva cancer or an 'Other' value.

The grade of a follicular lymphoma, assessed using the follicular lymphoma grading system.

The type of frozen section specimen collected for a pathology request an 'Other' value.

The body location used to describe the point of origin for a gastroenteropancreatic neuroendocrine tumour (GEP-NET) of the anus excluding lymph nodes or an 'Other' value.

The body location used to describe the point of origin for a gastroenteropancreatic neuroendocrine tumour (GEP-NET) of the appendix excluding lymph nodes or an 'Other' value.

The body location used to describe the point of origin for a gastroenteropancreatic neuroendocrine tumour (GEP-NET) of the colorectum excluding lymph nodes or an 'Other' value.

The body location used to describe the point of origin for a gastroenteropancreatic neuroendocrine tumour (GEP-NET) which is not a hepatic NET, pancreas NET, anus NET, colorectal NET, appendix NET, small intestine NET or stomach NET, excluding lymph nodes or an 'Other' value.

The body location used to describe the point of origin for a gastroenteropancreatic neuroendocrine tumour (GEP-NET) of the pancreas excluding lymph nodes or an 'Other' value.

The body location used to describe the point of origin for a gastroenteropancreatic neuroendocrine tumour (GEP-NET) of the stomach excluding lymph nodes or an 'Other' value.

The body location used to describe the point of origin for a gastroenteropancreatic neuroendocrine tumour (GEP-NET) excluding lymph nodes or an 'Other' value.

Lymph nodes used for diagnosis of gastrointestinal anal cancer or an 'Other' value.

The type of the primary gastrointestinal solid cancer being assessed and treated.

The body location used to describe the point of origin for colon cancer or an 'Other' value.

Lymph nodes used for diagnosis of gastrointestinal colorectal cancer or an 'Other' value.

Specimen collection metastecomy resection procedures used in the diagnosis of gastrointestinal colorectal cancer or an 'Other' value.

Body sites that are accessed by a surgeon during a operative or endoscopic resection procedure or an 'Other' value.

The body location used to describe the point of origin for colorectal cancer or an 'Other' value.

Specimen collection procedures used in small diagnostic procedures for the diagnosis of gastrointestinal colorectal cancer or an 'Other' value.

The body location used to describe the point of origin for cancer of the duodenum including ampulla of vater or an 'Other' value.

The body location used to describe the point of origin for cancer of the exocrine pancreas or an 'Other' value.

The body location used to describe the point of origin for hepatopancreaticobiliary cancer or an 'Other' value.

The body location used to describe the point of origin for cancer of the ileum and jejunum or an 'Other' value.

The body location used to describe the point of origin for cancer of the liver or an 'Other' value.

Lymph nodes used for diagnosis of gastrointestinal cancer or an 'Other' value.

The body location used to describe the point of origin for oesophageal cancer or an 'Other' value.

The body location used to describe the point of origin for pancreatic cancer or an 'Other' value.

The body location used to describe the point of origin for rectal cancer or an 'Other' value.

Specimen collection procedures used in the diagnosis of gastrointestinal cancer or an 'Other' value.

Lymph nodes used for diagnosis of gastrointestinal stomach cancer or an 'Other' value.

The body location used to describe the point of origin for stomach cancer or an 'Other' value.

The subcategory of the primary gastrointestinal solid cancer being assessed and treated.

The type of primary non prostate genitourinary solid cancer being assessed and/or treated.

The subcategory of the primary genitourinary solid cancer being assessed and treated.

The grade of a cancer

Grading systems used to assess the grade of one or more cancer types, or an 'Other' value.

The category of haematologic cancer being assessed and treated.

The subcategory of haematologic cancer being assessed and treated.

Intents or reasons for using a therapeutic procedure to treat haematological cancers.

The type of the primary head and neck solid cancer being assessed and treated.

The body location used to describe the point of origin for cancer of the hypopharynx or an 'Other' value.

The body location used to describe the point of origin for cancer of the larynx or an 'Other' value.

Lymph nodes used for diagnosis of head and neck cancer or an 'Other' value.

The body location used to describe the point of origin for cancer of the major salivary gland or an 'Other' value.

The body location used to describe the point of origin for cancer of the nasal cavity and/or paranasal sinus' or an 'Other' value.

The body location used to describe the point of origin for cancer of the nasal region or an 'Other' value.

The body location used to describe the point of origin for cancer of the nasopharynx or an 'Other' value.

The body location used to describe the point of origin for cancer of the jaw region or an 'Other' value.

The body location used to describe the point of origin for cancer of the head and neck which is not an ear, trachea, larynx, parapharyngeal, hypopharynx, oropharynx, nasopharynx, nasal, salivary gland, oral cavity or mobile tongue, thyroid or odontogenic primary, excluding skin topography and lymph nodes or an 'Other' value.

The subcategory of the primary head and neck solid cancer being assessed and treated.

The body location used to describe the point of origin for cancer of the head and neck and thyroid excluding skin topography and lymph nodes or an 'Other' value.

The type of health worker role - including pathologist, radiologist and surgeon.

The type of cancer recurrence used in a heamatology setting plus unknown and not applicable values.

The high-level body location used to describe the point of origin for all cancer types or an 'Other' value.

The type of indolent B cell lymphoma haematologic cancer being assessed and treated.

The type of indolent non-Hodgkin B cell lymphoma haematologic cancer being assessed and/or treated.

Test method procedures used in laboratory studies or an "other" value.

The side of a paired organ (e.g. left or right).

The side of a paired organ (e.g. left or right) or a 'Not applicable' value.

The side of a paired organ (e.g. left or right) or an 'Unknown' or 'Not applicable' value.

The side of a paired organ or midline structure, e.g. left, right, central.

The laterality of a paired organ (e.g. left, right, bilateral) or the side of the body relative to the midline (e.g. left side, right side, central or both sides) or 'Not applicable'.

The side of a paired organ (e.g. left or right) or an 'Unknown' value.

The type of the primary lower gastrointestinal solid cancer being assessed and treated.

The type of lymph node specimen collected for a pathology request or an 'Other' value.

The subcategory of lymphoma haematologic cancer being assessed and/or treated.

The type of the primary male genital solid cancer being assessed and treated, by systemic anti-cancer therapy (SACT).

Lymph nodes used for diagnosis of male genital cancer or an 'Other' value.

The body location used to describe the point of original for male genital cancer or an 'Other' value.

The type of mastocytosis haematologic cancer being assessed and treated.

The type of the primary central nervous system (CNS) solid cancer being assessed and treated, by medical oncology services.

The type of the primary endocrine solid cancer being assessed and treated my medical oncology services.

The type of the primary genitourinary solid cancer being assessed and treated, by medical oncology services.

The type of the primary gynaecological solid cancer being assessed and treated, by medical oncology services.

The type of the primary head and neck solid cancer being assessed and treated, by medical oncology services.

The body location used to describe the point of origin for cancer of the head and neck which is not an ear, trachea, larynx, parapharyngeal, hypopharynx, oropharynx, nasopharynx, nasal, salivary gland, oral cavity or mobile tongue, thyroid or odontogenic primary, including skin topography and lymph nodes or an 'Other' value.

The body location used to describe the point of origin for male genital cancer or an 'Other' value, used for medical oncology services.

The type of the primary head and neck other than oral cavity or mobile tongue primary, major salivary gland primary, odontogenic primary, nasal cavity and paranasal sinus primary, ear primary, pharynx, larynx and trachea primary solid cancer being assessed and treated by medical oncology services.

The body location used to describe the point of origin for skin cancer and/or melanoma or an 'Other' value for medical oncology services.

The body location used to describe the point of origin for a skin cancer or an 'Other' value for medical oncology services.

The type of the primary solid cancer being assessed and treated, by medical oncology services.

The subcategory of the primary solid cancer being assessed and treated by medical oncology services.

The type of the primary thoracic solid cancer being assessed and treated by medical oncology services.

Intents or reasons for using a therapeutic procedure to treat solid tumors under the supervision of a medical oncologist.

The body location used to describe the point of origin for testicular cancer or an 'Other' value, used for medical oncology services.

The body location used to describe the point of origin for urinary and male genital cancer or an 'Other' value, used for medical oncology services.

The subcategory of the primary thoracic cancer being assessed and treated by medical oncology services.

The type of the primary melanoma solid cancer being assessed and treated.

The relevant values to classify the onset of menopause for a patient e.g. premenopausal, perimenopausal or postmenopausal.

A body structure where cancer may be present, which crosses midline but should not be referred to in sides (e.g. non-symmetrical, non-specific and lateralisable structures).

A body structure where cancer may be present, which is symmetrical on the body's midline or an 'Other' value.

The type of myelodysplastic-myeloproliferative haematologic cancer being assessed and treated.

The type of myeloid proliferation and myeloid neoplasm haematologic cancer being assessed and treated.

The body location used to describe the point of origin for skin cancer of the nail or an 'Other' value.

The type of the primary nasal solid cancer being assessed and treated.

The morphologic abnormality used to describe a benign or reactive diagnosis recorded within the National Cervical Screening Programme (NCSP).

The status on whether the excision was complete or not, which is recorded within the National Cervical Screening Programme (NCSP).

The type of specimen collected, which is recorded within the National Cervical Screening Programme (NCSP).

The body location used to describe the point of origin for a cancer recorded within the National Cervical Screening Programme (NCSP).

The type of neoadjuvant therapy that has been performed (excluding neoadjuvant hormone therapy) or an 'Unknown' value.

A scoring system system used to measure a patient's response to neoadjuvant therapy or an 'Other' value.

The type of the primary neuroendocrine tumour gastroenteropancreatic (GEP) solid cancer being assessed and treated.

The type of the primary neuroendocrine tumour non-gastroenteropancreatic (non-GEP) solid cancer being assessed and treated.

The subcategory of the primary neuroendocrine solid cancer being assessed and/or treated.

The body location used to describe the point of origin for a neuroendocrine tumour (NET) of the breast excluding lymph nodes or an 'Other' value.

The body location used to describe the point of origin for a neuroendocrine tumour (NET) of the male genital system excluding lymph nodes or an 'Other' value.

The body location used to describe the point of origin for a neuroendocrine tumour (NET) of the urinary system excluding lymph nodes or an 'Other' value.

The type of non Hodgkin lymphoma haematologic cancer being assessed and/or treated.

Non-AJCC staging systems that may be used to classify the stage of a cancer diagnosis or an 'Other' value.

The reason why the procedure and/or test was not performed.

The grade of a breast cancer, assessed using the nuclear ductal carcinoma in situ grading system.

Observable entities used to represent the meaning of CanShare data elements.

The body location used to describe the point of origin for hepatopancreaticobiliary cancer which is not a liver, biliary or pancreas primary or an 'Other' value.

The body location used to describe the point of origin for cancer of the parathyroid excluding lymph nodes or an 'Other' value.

The performance status of the procedure and/or test.

The type of the primary pharynx and larynx and trachea solid cancer being assessed and treated.

The body location used to describe the point of origin for a neuroendocrine tumour of the pituitary gland excluding lymph nodes or an 'Other' value.

The type of polyp specimen (based on morphology) collected for a pathology request an 'Other' value.

The type of polyp profile on a specimen collected for a pathology request.

The result for a test (eg positive, negative), where more specific finding values are not available.

Presence of tumour findings in relation to prognostic factors of a cancer diagnosis.

The assessment for which the referral criteria for a procedure is established plus other value.

The status of a procedure.

Systems that may be used to score the prognostic factors of a cancer diagnosis or an "other value".

The type of beam energy which is used plan and deliver the radiation therapy treatment.

The planning technique used to plan the radiation therapy treatment.

The types of radiology, or an 'Other' value.

The type of cancer recurrence, e.g. local, regional plus unknown and not applicable values.

The revised stage groups for amyloidosis, defined using Mayo 2012 staging system.

The revised stage groups for primary cutaneous T-cell lymphoma, defined using TNM-B category staging system.

The type of cancer service that is currently, or should in the future, treat this cancer.

The side of a body structure that is symmetrical to the midline, e.g. left side, right side, both sides or central.

The side of a body structure that is symmetrical to the midline, e.g. left side, right side, both sides, central, or a 'definitely not present' value.

The simple performance status of the procedure and/or test i.e. performed or not performed.

The subcategory of the primary skin and melanoma solid cancer being assessed and treated.

The type of the primary skin solid cancer being assessed and treated.

The body location used to describe the point of origin for skin cancer of the extremity or an 'Other' value.

The body location used to describe the point of origin for skin cancer of the head and neck or an 'Other' value.

The body location used to describe the point of origin for skin cancer of the trunk or an 'Other' value.

The body location used to describe the point of origin for a skin cancer or an 'Other' value.

The body location used to describe the point of origin for abdomen and pelvis soft tissue cancer or an 'Other' value.

The type of the primary soft tissue and bone solid cancer being assessed and treated.

The subcategory of the primary soft tissue and bone solid cancer being assessed and treated.

The body location used to describe the point of origin for extremity soft tissue cancer or an 'Other' value.

The body location used to describe the point of origin for head and neck soft tissue cancer or an 'Other' value.

The body location used to describe the point of origin for skin soft tissue cancer or an 'Other' value.

The body location used to describe the point of origin for thoracic soft tissue cancer or an 'Other' value.

The type of the primary solid cancer being assessed and treated, by systemic anti-cancer therapy (SACT).

Non-AJCC staging systems that may be used to classify the stage of a solid tumour or an 'Other' value.

Systems that may be used to classify the stage of a solid tumour or an "other value".

The subcategory of the primary solid cancer being assessed and treated.

The category of specimen collected for a pathology request an 'Other' value.

Whether the category of specimen is a biopsy or an excision for a pathology request form.

The type of specimen dimension being observed.

Stage classification used to define timing of staging.

The category of the primary cancer being assessed and treated.

An additional qualification of the margin description to confirm if margin is proximal or distal.

The type of margin observed in a surgical cancer setting.

The reason why the test failed.

The reason why the test result is inconclusive.

The type of the primary thoracic solid cancer being assessed and treated.

The body location used to describe the lobe of the lung.

Lymph nodes used for diagnosis of thoracic lung cancer or an 'Other' value.

Lymph nodes used for diagnosis of thoracic cancer or an 'Other' value.

The body location used to describe the point of origin mesothelioma or an 'Other' value used for medical oncology treatment services.

The body location used to describe the point of origin for thorax cancer or an 'Other' value used for medical oncology treatment services.

The body location used to describe the point of origin for soft tissue sarcoma of thorax and mediastinum primary or an 'Other' value.

The body location used to describe the point of origin for thymus cancer or an 'Other' value.

The body location used to describe the point of origin for thorax cancer or an 'Other' value.

The body location used to describe the point of origin for cancer of the thyroid excluding lymph nodes or an 'Other' value.

The body location used to describe the point of origin for cancer of the thyroid excluding lymph nodes or an 'Other' value.

Treatment intents or reasons for using a therapeutic procedure to treat cancer.

The focality of a tumour.

The suspected origin of the tumour clinically assessed.

The unknown body location of a cancer.

The type of the primary upper gastrointestinal solid cancer being assessed and treated.

The body location used to describe the point of origin for upper gastrointestinal cancer or an 'Other' value.

Lymph nodes used for diagnosis of kidney cancer or an 'Other' value.

The body location used to describe the point of origin for kidney cancer or an 'Other' value.

Lymph nodes used for diagnosis of urinary and male genital cancer or an 'Other' value.

Lymph nodes used for diagnosis of penis cancer or an 'Other' value.

The body location used to describe the point of origin for prostate cancer or an 'Other' value.

Lymph nodes used for diagnosis of renal pelvis and ureter cancer or an 'Other' value.

The body location used to describe the point of origin for renal pelvis and ureter cancer or an 'Other' value.

Lymph nodes used for diagnosis of renal pelvis cancer or an 'Other' value.

The body location used to describe the point of origin for testicular adnexa cancer or an 'Other' value.

The body location used to describe the point of origin for testicular cancer or an 'Other' value.

Lymph nodes used for diagnosis of testis cancer or an 'Other' value.

The body location used to describe the point of origin for testis cancer or an 'Other' value.

Lymph nodes used for diagnosis of urinary bladder cancer or an 'Other' value.

The body location used to describe the point of origin for urinary bladder cancer or an 'Other' value.

The type of the primary urinary system solid cancer being assessed and treated.

Lymph nodes used for diagnosis of urinary system cancer or an 'Other' value.

The body location used to describe the point of original for urinary system cancer or an 'Other' value.

TNM stage classification used to define timing of clinical staging.

Whether there is obstruction or perforation of the colorectum.

Whether or not obstruction of colorectum is or is not identified.

Whether or not perforation of colorectum is or is not identified.

NZ Ethnicity level 1 codes only.

The type of the primary lung solid cancer being assessed and treated.

Histologies used for brain primaries by medical oncology services, from WHO Classification of Tumours, Central Nervous System Tumours (latest edition) - 2. Gliomas, glioneuronal tumours, and neuronal tumours, 3. Choroid plexus tumours, 4. Embyronal tumours, 5. Pineal tumours, 7. Meningioma, 8. Mesenchymal, non-meningothelial tumours involving the CNS, 9. Melanocytic tumours, 11. Germ cell tumours, 12. Tumours of the sellar region or an 'Other' value.

The type of the primary endocrine and neuroendocrine tumour solid cancer being assessed and treated by medical oncology services.

Whether or not perforation of colon is or is not identified.

The purpose of the surgical procedure.

Toxicity factors that may result in the discontinuation of a systemic anti-cancer therapy (SACT) treatment.

The subcategory of the primary cancer being assessed and treated by medical oncology and heamatology services.

A LOINC FHIR ValueSet of NZPOCS Observation Code Set

The role a practitioner holds.

IPS Pregnancies Summary

IPS Expected Delivery Date Method

IPS Pregnancy Status

Problem Severity. The condition-severity value set from the base Condition resource is now the preferred binding for IPS. This value set of LOINC answer codes is retained as an additional binding for backward compatibility with the prior IPS release.

This value set includes codes from SNOMED Clinical Terms®: descendants of 404684003 |Clinical finding (finding) |, descendants of 243796009 |Situation with explicit context (situation)| and descendants of 272379006 |Event (event)|. The descendants of 71388002 |Procedure (procedure)| (which were included in the CORE problem list) are not included, as they are expected to be represented separately in the History of Procedures Section.

This value set is defined as the union of: (a) Blood group [Type]; (b) Presence/Absence Indicators (2.16.840.1.113883.11.22.52) (c) Microorganisms (2.16.840.1.113883.11.22.49)

This value set includes codes from SNOMED Clinical Terms (SNOMED CT®) that are included in: all descendants of 106253005 |Histologic grading differentiation AND/OR behavior (qualifier value)|, all descendants of 373369003 |Finding of histologic grading differentiation AND/OR behavior (finding)|, all descendants of 399981008 |Neoplasm and/or hamartoma (disorder)|.

Value Set Definition:

LOINC {STATUS in {ACTIVE}, CLASSTYPE in {1}, CLASS in {CYTO, HL7.CYTOGEN, HL7.GENETICS, MOLPATH, MOLPATH.*, PATH, PATH.*}}

Presence/Absence value set

Value Set Definition: LOINC {CLASS in {RAD}}

IPS Specimen Collection Method

IPS Specimen Type value set. This value set includes a set of codes from SNOMED CT that may be used to represent specimen types.

Value set to support FHIR resource for identifying the rheumatic fever care plan being provided.

This value set includes some taken and not taken reason codes from SNOMED CT - provided as an exemplar

Unified Code for Units of Measure (UCUM). This value set includes all UCUM codes

FHIR ValueSet for UKPUL

This value set indicates the allowed vital sign result types. The LOINC code for Vitals Signs panel (85353-1) is a grouping structure for a set of vital signs and includes related links (with type=has-member) to the Observations in this set (e.g. respiratory rate, heart rate, BP). The Blood pressure panel (85354-9) is used to group the component observations Systolic blood pressure (8480-6) and Diastolic blood pressure (8462-4).

All codes for https://standards.digital.health.nz/ns/admission-source-code

All codes for http://terminology.hl7.org/CodeSystem/adverse-event-severity

All codes for https://standards.digital.health.nz/ns/alias-type-code

All codes for http://hl7.org/fhir/allergy-intolerance-category

All codes for http://hl7.org/fhir/allergy-intolerance-type

All codes for http://terminology.hl7.org/CodeSystem/allergyintolerance-clinical

All codes for https://nzhts.digital.health.nz/fhir/CodeSystem/anzsco

All codes for http://canshare.co.nz/fhir/CodeSystem/canshare-moh-refcrit-colonoscopy-2w

All codes for https://standards.digital.health.nz/ns/clinical-code-type-code

All codes for http://terminology.hl7.org/CodeSystem/condition-ver-status

All codes for https://standards.digital.health.nz/ns/contact-point-purpose-code

All codes for https://standards.digital.health.nz/ns/dhb-code

All codes for https://standards.digital.health.nz/ns/domicile-code

All codes for https://standards.digital.health.nz/ns/ethnic-group-level-4-code

All codes for https://standards.digital.health.nz/ns/hpi-practitioner-role-status-reason-code

All codes for urn:iso:std:iso:3166

All codes for https://standards.digital.health.nz/ns/iwi-code

All codes for https://standards.digital.health.nz/ns/nz-datum-code

All codes for https://standards.digital.health.nz/ns/nz-ethnic-group-codes

All codes for https://standards.digital.health.nz/ns/nzmt-type-code

All codes for https://standards.digital.health.nz/ns/oral-enrolment-termination-reason-code

All codes for https://standards.digital.health.nz/ns/practitioner-additional-authorisation-code

All codes for https://standards.digital.health.nz/ns/practitioner-scope-of-practice-code

All codes for https://standards.digital.health.nz/ns/skin-to-skin-contact-end-reason-code

All codes for http://hl7.org/fhir/sid/cvx

Anatomical Therapeutic Chemical (ATC) classification system

Anatomical Therapeutic Chemical (ATC) classification system

Additional authorisations that a practitioner is authorised to practice or prescribe.

The gender of a person used for administrative purposes.

Admission source code for use when reporting into National Collections

Admission types to be used for reporting into National Collections

Agency type code to be used in reporting to National Collection

Estimate of the potential clinical harm, or seriousness, of a reaction to an identified substance.

Clinical assessment of the severity of a reaction event as a whole, potentially considering multiple different manifestations.

Terms for clinicians to identify when symptoms started to determine if a person is eligible for the COVID-19 antiviral

Australian and New Zealand Standard Industrial Classification

Canshare testing non-snomed concepts

Clinical code type code for use when reporting into National Collections

Clinical coding system code to be used for reporting to National Collections

Preferred value set for Condition Clinical Status.

The purpose of a ContactPoint - what it is used for.

Country - New Zealand Standard Classification 2 alpha

New Zealand codes for Coverage category types

New Zealand codes for Coverage Types

DSM-IV

Possible datum codes

Te Whatu Ora list of domicile codes

EDQM - Standard Terms used in Switzerland (aggregations of codes of ValueSets RouteOfAdministration, Dose Form, see original codes system defined in https://standardterms.edqm.eu/#)

Some sort of funded programme

ISO 3166-1 establishes codes that represent the current names of countries, dependencies, and other areas of particular geopolitical interest, on the basis of country names obtained from the United Nations.

Description: Codes for the representation of names of languages — Part 2: Alpha-3 code, is the second part of the ISO 639 standard, which lists codes for the representation of the names of languages. The three-letter codes given for each language in this part of the standard are referred to as Alpha-3 codes. There are 487 entries in the list of ISO 639-2 codes. There are 21 languages that have alternative codes for bibliographic or terminology purposes, this code system only contains those with terminology purposes. Administered by SIL

Description: ISO 639-3 is a code that aims to define three-letter identifiers for all known human languages. At the core of ISO 639-3 are the individual languages already accounted for in ISO 639-2. The large number of living languages in the initial inventory of ISO 639-3 beyond those already included in ISO 639-2 was derived primarily from Ethnologue (15th edition). Additional extinct, ancient, historic, and constructed languages have been obtained from Linguist List. Administered by SIL

The feeding method of an infant at various stages post delivery

All possible sources of information

Iwi and iwi-releated groups

LOINC is a common language (set of identifiers, names, and codes) for clinical and laboratory observations.

LOINC is a common language (set of identifiers, names, and codes) for clinical and laboratory observations.

LOINC is a common language (set of identifiers, names, and codes) for clinical and laboratory observations.

A FHIR CodeSystem of NZPOCS Observation Code Set - NZ Specific Code

Language classification code

Codes to record a person’s ethnicity, drawn from Level 4 of the Ethnicity code system described here

FHIR CodeSystem for MedDRA LLT 26.0

FHIR CodeSystem for MedDRA LLT 27.0

FHIR CodeSystem for MedDRA LLT 26.1

Medication Status Codes

Whether the application produces or consumes documents.

My New CS

Stats NZ's Māori descent codes

Is this person a NZ Citizen

Additional codes to be incorporated with HL7 v3 Value Set Purpose of Use

NZ Residency status

Codes identifying the lifecycle stage of a care plan request.

The verification status to support or decline the clinical status of the condition or diagnosis.

Codes identifying the lifecycle stage of a request.

Codes identifying the lifecycle stage of a service request (e.g. diagnostic tests, therapies, pharmacist medication review).

The status of the diagnostic report.

The 6 week referral criteria published by the Ministry of Health for outpatient colonoscopies.

A categorisation used to prioritise booking a first specialist assessment, for radiation oncology services.

A categorisation used to prioritise the start of radiation therapy treatment.

A FHIR CodeSystem of Australian and Ethnicity New Zealand Standard Classification

SNOMED CT is the most comprehensive and precise clinical health terminology product in the world, owned and distributed around the world by The International Health Terminology Standards Development Organisation (IHTSDO).

SNOMED CT is the most comprehensive and precise clinical health terminology product in the world, owned and distributed around the world by The International Health Terminology Standards Development Organisation (IHTSDO).

SNOMED CT is the most comprehensive and precise clinical health terminology product in the world, owned and distributed around the world by The International Health Terminology Standards Development Organisation (IHTSDO).

SNOMED CT is the most comprehensive and precise clinical health terminology product in the world, owned and distributed around the world by The International Health Terminology Standards Development Organisation (IHTSDO).

Number of vessels identified in the umbilical cord

SNOMED CT is the most comprehensive and precise clinical health terminology product in the world, owned and distributed around the world by The International Health Terminology Standards Development Organisation (IHTSDO).

Omaha System CodeSystem including various domains.

Primary Healthcare Organization

The reason for the current status of PractitionerRole

The code list represents the current practicing status of the Provider Person as per their registration with an RA.

This list to support rheumatic fever collection.

SNOMED CT is the most comprehensive and precise clinical health terminology product in the world, owned and distributed around the world by The International Health Terminology Standards Development Organisation (IHTSDO).

SNOMED CT is the most comprehensive and precise clinical health terminology product in the world, owned and distributed around the world by The International Health Terminology Standards Development Organisation (IHTSDO).

SNOMED CT is the most comprehensive and precise clinical health terminology product in the world, owned and distributed around the world by The International Health Terminology Standards Development Organisation (IHTSDO).

SNOMED CT is the most comprehensive and precise clinical health terminology product in the world, owned and distributed around the world by The International Health Terminology Standards Development Organisation (IHTSDO).

SNOMED CT is the most comprehensive and precise clinical health terminology product in the world, owned and distributed around the world by The International Health Terminology Standards Development Organisation (IHTSDO).

A classification of the type or range of health services that a practitioner is authorised to provide, as determined by the Responsible Authority or other statutory authority (e.g. PHARMAC), that is, what the practitioner can or cannot do. It includes Scope of Practice as defined by the Health Practitioners Competence Assurance Act 2003, any special authorisations granted, and any conditions or limitations imposed by the Responsible Authority.

Reason why initial skin to skin contact was ended

SNOMED CT identifiers assigned to Rheumatic Fever concepts that will not be available until April 2024 edition. Codesystem need to be retired once they have been uploaded in SNOMED NZ Edition

Used in Organization and Location to indicate what is the type of Alias

The Unified Code for Units of Measure (UCUM) is a code system intended to include all units of measures being contemporarily used in international science, engineering, and business. The purpose is to facilitate unambiguous electronic communication of quantities together with their units. The focus is on electronic communication, as opposed to communication between humans. A typical application of The Unified Code for Units of Measure are electronic data interchange (EDI) protocols, but there is nothing that prevents it from being used in other types of machine communication.

HISO 10050 Uterotonic drugs administered status, as part of the third stage of labour.

The CDC's National Center of Immunization and Respiratory Diseases developed and maintains the CVX (vaccine administered) code set. It includes both active and inactive vaccines available in the US.

canshare-test-nonsnomed

country code 4 numeric

A set of codes specifying the motivation, cause, or rationale of an Act, when such rationale is not reasonably represented as an ActRelationship of type "has reason" linking to another Act. Examples: Example reasons that might qualify for being coded in this field might be: "routine requirement", "infectious disease reporting requirement", "on patient request", "required by law".